Thomas Knoepfel

Thomas Knoepfel

Auto-generated profile, based on publicly available information

Thomas Knoepfel

Novartis Biomedical Research Novartis Campus 4056 Basel Switzerland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2004 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
TKThomas F. Knöpfel
Thomas F. Knöpfel
PAPatrick Aschwanden
Patrick Aschwanden
TITakashi Ichikawa
Takashi Ichikawa
TWTakumi Watanabe
Takumi Watanabe
ECErick Moran Carreira
Erick Moran Carreira
A short and modular synthesis of novel P,N ligands (pinap; see scheme; X=O or NH) is presented. A covalently bound chiral group allows the separation of the atropisomeric diastereomers, thus avoiding resolution involving chiral Pd–amine complexes. The utility of the ligands is demonstrated for three reactions catalyzed by different transition metals; in each case products are obtained with high enantiomeric excess (up to 99 % ee).

16 June 2005 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TKThomas F. Knöpfel
Thomas F. Knöpfel
PZPablo Zarotti
Pablo Zarotti
TITakashi Ichikawa
Takashi Ichikawa
ECErick Moran Carreira
Erick Moran Carreira

23 April 2003 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TKThomas F. Knöpfel
Thomas F. Knöpfel
ECErick Moran Carreira
Erick Moran Carreira

15 September 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RFRobin A. Fairhurst
Robin A. Fairhurst
TKThomas Knoepfel
Thomas Knoepfel
NBNicole Buschmann
Nicole Buschmann
CLCatherine Leblanc
Catherine Leblanc
RMRobert Mah
Robert Mah
PFPascal Furet
Pascal Furet

1 December 2019 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
AWAndreas Weiss
Andreas Weiss
FAFlavia Adler
Flavia Adler
ABAlexandra Buhles
Alexandra Buhles
CSChristelle Stamm
Christelle Stamm
RFRobin A. Fairhurst
Robin A. Fairhurst
DPDiana Graus Porta
Diana Graus Porta
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and it is the third leading cause of cancer-related deaths worldwide. Recently, aberrant signaling through the FGF19/FGFR4 axis has been implicated in HCC. Here, we describe the development of FGF401, a highly potent and selective, first in class, reversible-covalent small-molecule inhibitor of the kinase activity of FGFR4. FGF401 is exquisitely selective for FGFR4 versus the other FGFR paralogues FGFR1, FGFR2, FGFR3, and all other kinases in the kinome. FGF401 has excellent drug-like properties showing a robust pharmacokinetic/pharmacodynamics/efficacy relationship, driven by a fraction of time above the phospho-FGFR4 IC90 value. FGF401 has remarkable antitumor activity in mice bearing HCC tumor xenografts and patient-derived xenograft models that are positive for FGF19, FGFR4, and KLB. FGF401 is the first FGFR4 inhibitor to enter clinical trials, and a phase I/II study is currently ongoing in HCC and other solid malignancies.

1 August 2003 in Tetrahedron
Verified
Journal Article
Closed access
SRStefan Reber
Stefan Reber
TKThomas F Knöpfel
Thomas F Knöpfel
ECErick Moran Carreira
Erick Moran Carreira